Inthera Bioscience is an emerging Swiss biotechnology company that develops innovative and highly effective therapies against currently incurable cancers. The company is tackling “undruggable” targets with innovative chemistry for the design of small molecule inhibitors of intracellular protein-protein interactions. The most advanced of these first-in-class therapeutics, a modulator of dysregulated transcription, is currently progressing towards clinical stage.

Team Members
more about
Cheryl Zimberlin
Investment Director
more about
Christian Uhrich
all portfolio news